 | |
| Clinical data | |
|---|---|
| Other names | PHENETHLAD; PHENETHY-LAD; PHENETHYLAD; 6-(β-Phenethyl)-6-nor-LSD;N-Phenethyl-nor-LSD;N,N-Diethyl-6-phenethyl-6-norlysergamide;N,N-Diethyl-6-(2-phenylethyl)-9,10-didehydroergoline-8β-carboxamide |
| ATC code |
|
| Identifiers | |
| |
| PubChemCID | |
| ChemSpider | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C27H31N3O |
| Molar mass | 413.565 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
PHENETH-LAD, orPHENETHY-LAD, also known as6-(β-phenethyl)-6-nor-LSD, is adrug of thelysergamide family related tolysergic acid diethylamide (LSD).[1][2][3][4][5] It is thederivative of LSD in which themethyl group at the 6 position has been replaced with aphenylethylmoiety.[1][2][3]
The drug failed to substitute for LSD in rodentdrug discrimination tests, with a maximum of 25 or 50% LSD-appropriate responding at the highest assessed dose.[1][4][5] Unlike other 6-substituted lysergamides, PHENETH-LAD was not assessed at theserotonin receptors.[1][5] According toAlexander Shulgin in his bookTiHKAL (Tryptamines I Have Known and Loved), PHENETH-LAD produced no effects in humans at a dose of 500 μg.[3] He has specified the potentially active dose as being >350 μg and itshallucinogenicpotency being less than 30% of that of LSD.[2][6]
PHENETH-LAD was first described in thescientific literature by Andrew Joseph Hoffman of the lab ofDavid E. Nichols atPurdue University in 1985.[4] Its effects in humans were first described by Shulgin by 1994.[6][3]
only partial generalization occurred to norLSD and the N(6)-2-phenethyl derivative at the doses tested. [...] Table 6. 5-HT1 binding affinity of N(6)-alkyl norLSD derivatives. [...] Table 7. 5-HT2 binding affinity of N(6)-alkyl norLSD derivatives. [...] Table 9. Drug discrimination testing results. [...]
 | Thishallucinogen-related article is astub. You can help Wikipedia byexpanding it. |